Understanding the mechanism of action (MOA) of a candidate compound is a key step in the drug development process. In particular, delineating the MOA of cancer immunotherapeutics relies on the characterization of the anti-tumor immune response within the tumor but also at the periphery. Such ancillary approaches can also support the research of innovative and robust biomarkers, for subject stratification in trials.
Biomarkers quantification in biological samples
Our biomarker services include RT-qPCR analysis, explorations of relevant markers in plasma by ELISA, or FACS immunophenotyping of Peripheral Blood Mononulclear Cells (PBMCs), cells recovered from spleen, ganglia, or tumors themselves. This is the ideal complement to fully understand how candidate immunomodulatory drugs impact on the recruitment & functionality of distinctive immune cells, and how they modify the expression/synthesis/secretion of mediators relevant to tumor growth.
Innovative biomarkers to classify clinical response to anti-CTLA4 in a CT26 tumor-bearing mice model. Mice were challenged with CT26 and exposed to anti-CTLA4 antibody. Dendritic cells (CD11c+) from spleen were recovered and subjected to multiple RT-qPCR analysis to finaly identify a key markers able to distinguish responders and not responders animals. A related marker was also found at plasmatic level, 13 days after tumor cell inoculation.
For an ancillary study design please inquire using the dialog box!